MIRM Mirum Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: MIRM
Price (delayed)
$70.1
Market cap
$3.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$3.61B
Relative Growth:
Rel. Growth:
86
Relative Strength:
Rel. Strength:
86
Relative Valuation:
Rel. Valuation:
10
Relative Profitability:
Rel. Profitability:
42
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
Highlights
The company's gross profit has surged by 77% YoY and by 16% QoQ
The revenue has soared by 62% YoY and by 13% from the previous quarter
The quick ratio has declined by 6% year-on-year and by 3.1% since the previous quarter
Key stats
What are the main financial stats of MIRM
Market
Valuations
Earnings
Shares outstanding
50.24M
Market cap
$3.52B
Enterprise value
$3.61B
Price to earnings (P/E)
N/A
Price to book (P/B)
13.61
Price to sales (P/S)
8.12
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.41
Revenue
$429.16M
Gross profit
$339.14M
Operating income
-$57.08M
Net income
-$58.56M
EBIT
-$43.01M
EBITDA
-$17.2M
Free cash flow
$8.63M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
$0.17
Book value per share
$5.15
Revenue per share
$8.63
TBVPS
$9.81
Total assets
$725.83M
Total liabilities
$470.67M
Debt
$316.82M
Equity
$255.16M
Working capital
$308.6M
Debt to equity
1.24
Current ratio
3.13
Quick ratio
2.84
Net debt/EBITDA
-5.13
Margins
Efficiency
Dividend
EBITDA margin
-4%
Gross margin
79%
Net margin
-13.6%
Operating margin
-13.3%
Return on assets
-8.5%
Return on equity
-24.8%
Return on invested capital
-10.5%
Return on capital employed
-7.4%
Return on sales
-10%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIRM stock price
How has the Mirum Pharmaceuticals stock price performed over time
Intraday
0.01%
1 week
-2.91%
1 month
-3.35%
1 year
70.6%
YTD
69.53%
QTD
-4.38%
Financial performance
How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$429.16M
Gross profit
$339.14M
Operating income
-$57.08M
Net income
-$58.56M
Gross margin
79%
Net margin
-13.6%
The company's gross profit has surged by 77% YoY and by 16% QoQ
The operating margin has soared by 68% YoY and by 34% from the previous quarter
The company's net margin has surged by 67% YoY and by 33% QoQ
The revenue has soared by 62% YoY and by 13% from the previous quarter
Price vs fundamentals
How does MIRM's price correlate with its fundamentals
Growth
What is Mirum Pharmaceuticals's growth rate over time
Valuation
What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
13.61
P/S
8.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.41
The EPS has grown by 49% YoY and by 25% from the previous quarter
MIRM's price to book (P/B) is 106% higher than its 5-year quarterly average of 6.6 and 51% higher than its last 4 quarters average of 9.0
Mirum Pharmaceuticals's equity has increased by 11% YoY and by 9% from the previous quarter
The revenue has soared by 62% YoY and by 13% from the previous quarter
MIRM's price to sales (P/S) is 42% lower than its 5-year quarterly average of 14.1 but 38% higher than its last 4 quarters average of 5.9
Efficiency
How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 72% YoY and by 38% from the previous quarter
The ROIC has soared by 63% YoY and by 33% from the previous quarter
Mirum Pharmaceuticals's return on assets has increased by 49% YoY and by 26% QoQ
The ROE has increased by 44% YoY and by 26% QoQ
Dividends
What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIRM.
Financial health
How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 54% higher than its total liabilities
MIRM's total assets is up by 10% YoY and by 5% QoQ
The total liabilities has grown by 9% YoY and by 3% from the previous quarter
The company's debt is 24% higher than its equity
Mirum Pharmaceuticals's equity has increased by 11% YoY and by 9% from the previous quarter
The debt to equity has contracted by 10% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.